Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.
2 reports, 2 independent
Updated Fri 00:00
Still developing
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Raymond James Financial reaffirmed a strong-buy rating and Morgan Stanley set a $25.00 price objective for VIR Biotechnology.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Needham boosted target price and a new insider sale was disclosed for VIR Biotechnology.1 source
Rating updates and price target set for VIR Biotechnology by major financial firms.1 source
Keep exploring
The entities involved
-
VIR Biotechnology
biotech company
Nothing else this week.
-
Raymond James Financial
American Investment Bank and Financial Services Firm
-
Morgan Stanley
U.S. investment bank
Related events
- Raymond James Financial reaffirmed its outperformance rating for Amazon.com, Inc. on October 25, 2026.
- Raymond James Financial and Benchmark provided updated market performance and buy ratings for Malibu Boats.
- Raymond James Financial reiterated its outperform rating and price target for Lumentum Holdings Inc., while Jefferies Financial Group also reissued a buy rating and price objective.
- Financial firms Raymond James, CITIC Securities, and Amundi issued rating updates and target price changes for Apple Inc. stock.
- Raymond James Financial issued an outperform rating and Truist Financial reduced its price target on Arrow Electronics.